172 related articles for article (PubMed ID: 23775877)
1. Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.
te Beek ET; Tatosian D; Majumdar A; Selverian D; Klaassen ES; Petty KJ; Gargano C; van Dyck K; McCrea J; Murphy G; van Gerven JM
J Clin Pharmacol; 2013 Aug; 53(8):846-56. PubMed ID: 23775877
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.
te Beek ET; Zoethout RW; Bani MS; Andorn A; Iavarone L; Klaassen ES; Fina P; van Gerven JM
J Psychopharmacol; 2012 Feb; 26(2):303-14. PubMed ID: 22219221
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
te Beek ET; Hay JL; Bullman JN; Burgess C; Nahon KJ; Klaassen ES; Gray FA; van Gerven JM
Br J Clin Pharmacol; 2013 May; 75(5):1328-39. PubMed ID: 23067311
[TBL] [Abstract][Full Text] [Related]
4. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
[TBL] [Abstract][Full Text] [Related]
5. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
[TBL] [Abstract][Full Text] [Related]
7. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
[TBL] [Abstract][Full Text] [Related]
8. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
[TBL] [Abstract][Full Text] [Related]
9. Influence of a neurokinin-1 receptor antagonist (aprepitant) on gastric sensorimotor function in healthy volunteers.
Ang D; Pauwels A; Akyuz F; Vos R; Tack J
Neurogastroenterol Motil; 2013 Dec; 25(12):e830-8. PubMed ID: 23991829
[TBL] [Abstract][Full Text] [Related]
10. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
[TBL] [Abstract][Full Text] [Related]
11. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.
Hoch M; Hay JL; Hoever P; de Kam ML; te Beek ET; van Gerven JM; Dingemanse J
Eur Neuropsychopharmacol; 2013 Feb; 23(2):107-17. PubMed ID: 22658401
[TBL] [Abstract][Full Text] [Related]
12. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
Rosenzweig P; Patat A; Zieleniuk I; Cimarosti I; Allain H; Gandon JM
Clin Pharmacol Ther; 1998 Aug; 64(2):211-22. PubMed ID: 9728902
[TBL] [Abstract][Full Text] [Related]
13. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.
García-Gea C; Martínez J; Ballester MR; Gich I; Valiente R; Antonijoan RM
Hum Psychopharmacol; 2014 Mar; 29(2):120-32. PubMed ID: 24395298
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
Majumdar AK; Howard L; Goldberg MR; Hickey L; Constanzer M; Rothenberg PL; Crumley TM; Panebianco D; Bradstreet TE; Bergman AJ; Waldman SA; Greenberg HE; Butler K; Knops A; De Lepeleire I; Michiels N; Petty KJ
J Clin Pharmacol; 2006 Mar; 46(3):291-300. PubMed ID: 16490805
[TBL] [Abstract][Full Text] [Related]
15. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system effects of haloperidol on THC in healthy male volunteers.
Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
[TBL] [Abstract][Full Text] [Related]
17. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers.
Dumont GJ; Schoemaker RC; Touw DJ; Sweep FC; Buitelaar JK; van Gerven JM; Verkes RJ
J Psychopharmacol; 2010 Feb; 24(2):155-64. PubMed ID: 19164498
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
19. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.
Hallam KT; Olver JS; McGrath C; Norman TR
Hum Psychopharmacol; 2003 Dec; 18(8):619-25. PubMed ID: 14696021
[TBL] [Abstract][Full Text] [Related]
20. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.
Kwako LE; George DT; Schwandt ML; Spagnolo PA; Momenan R; Hommer DW; Diamond CA; Sinha R; Shaham Y; Heilig M
Psychopharmacology (Berl); 2015 Jan; 232(1):295-304. PubMed ID: 25030801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
